Clinical Trial Update: A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer [Phase 2]

View source ↗

Summary

A completed Phase 2 randomized trial comparing intravesical gemcitabine monotherapy against mitomycin C for intermediate-risk non-muscle invasive bladder cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-muscle Invasive Bladder Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Mitomycin-C (mitomycin C)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Superficial Bladder Cancer | Phase 2 | Status: COMPLETED